Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional <i>in vitro</i> models of vascular inflammation
These results indicate that our novel anti-VCAM-1 mAbs can effectively inhibit monocyte adhesion and transmigration <i>in vitro</i>, supporting the therapeutic rationale of VCAM-1 immunoblockade for the targeted treatment of atherosclerosis.
Authors
- Hang T. Ta (ORCID: https://orcid.org/0000-0003-1188-0472)
- B. V. P. Perera
- Yuao Wu (ORCID: https://orcid.org/0000-0003-4384-1195)
- Lucía F. Zacchi (ORCID: https://orcid.org/0000-0001-6217-1380)
- Jessica R Pickett
Institutions
- Griffith University (AU)
- The University of Queensland (AU)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/abt/tbaf025
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian National Fabrication Facility
- Australian Government
- National Heart Foundation of Australia
- Griffith University
- Therapeutic Innovation Australia
- Medical Research Council
- National Health and Medical Research Council